Current Diabetes Reports (2023) 23:31–42
https://doi.org/10.1007/s11892-023-01498-z

OBESITY (KM GADDE AND P SINGH, SECTION EDITORS)

Weight Regain After Bariatric Surgery: Scope of the Problem, Causes, Prevention, and Treatment

Sabrena F. Noria[1] · Rita D. Shelby[2] · Katelyn D. Atkins[3] · Ninh T. Nguyen[4] · Kishore M. Gadde[4]

Accepted: 9 December 2022 / Published online: 8 February 2023

Abstract

Purpose of Review Although bariatric surgery is the most effective treatment of severe obesity, a proportion of patients experience clinically significant weight regain (WR) with further out from surgery. The purpose of this review is to summarize the prevalence, predictors, and causes of weight regain.

Recent Findings Estimating the prevalence of WR is limited by a lack of consensus on its definition. While anatomic failures such as dilated gastric fundus after sleeve gastrectomy and gastro-gastric fistula after Roux-en-Y gastric bypass can lead to WR, the most common causes appear to be dysregulated/maladaptive eating behaviors, lifestyle factors, and physiological compensatory mechanisms. To date, dietary, supportive, behavioral, and exercise interventions have not demonstrated a clinically meaningful impact on WR, and there is limited evidence for pharmacotherapy.

Summary Future studies should be aimed at better defining WR to begin to understand the etiologies. Additionally, there is a need for non-surgical interventions with demonstrated efficacy in rigorous randomized controlled trials for the prevention and reversal of WR after bariatric surgery.

Keywords Obesity · Bariatric surgery · Weight regain · Behavior therapy · Antiobesity drugs

Introduction

During 2017–2018, 42% of adults in the USA had obesity (body mass index, BMI ≥ 30 kg/m^2) and 9% had severe obesity (BMI ≥ 40 kg/m^2) [1] with these prevalence rates projected to rise to 49% and 24%, respectively, by 2030 [2]. Obesity is associated with numerous chronic diseases including type 2 diabetes (T2D), hypertension, dyslipidemia, cardiovascular disease, nonalcoholic fatty liver disease, obstructive sleep apnea [3], and increased risk of hospitalization for COVID-19 with poorer outcomes [4–6]. Weight loss of 5–10%, if sustained long-term, can lead to improvement of obesity-related comorbidities [3, 7]. Whereas lifestyle interventions are recommended, they are hard to implement in primary care practices, and have limited long-term efficacy, primarily due to poor adherence [8–11]. Currently approved antiobesity drugs have yielded an average placebo-subtracted weight loss of 3–11% at 1 year in phase 3 clinical trials with daily oral phentermine/topiramate or weekly subcutaneous semaglutide demonstrating the most efficacy [12, 13].

Currently, bariatric surgery is the most effective treatment for obesity with clinically significant long-term weight loss [14–16] along with amelioration or resolution of obesity-related comorbidities including T2D [17–20], hypertension [21, 22], and dyslipidemia [23]. There is evidence from observational studies that bariatric surgery is associated with a reduction in major adverse cardiovascular events [24–27] and mortality [28–31]. The increased popularity of bariatric surgery is evidenced by the fact that > 600,000 surgeries are performed annually worldwide and > 256,000 in the USA alone in 2019, with sleeve gastrectomy (SG; 59%) and

This article is part of the Topical collection on Obesity

✉ Sabrena F. Noria
Sabrena.Noria@osumc.edu

[1] Department of Surgery, Division of General and Gastrointestinal Surgery, The Ohio State University, N718 Doan Hall, 410 W 10th Ave, Columbus, OH 43210, USA

[2] Department of Plastic and Reconstructive Surgery, University of Miami, Miller School of Medicine, 1600 NW 10th Ave #1140, Miami, FL 33136, USA

[3] Pennington Biomedical Research Center, 6400 Perkins Rd, Baton Rouge, LA 70808, USA

[4] Department of Surgery, University of California Irvine, 3800 W Chapman Ave, Orange, CA 92868, USA

Roux-en-Y gastric bypass (RYGB; 18%) being the most common procedures [32].

While bariatric surgery is generally superior to non-surgical weight loss interventions, a significant proportion of patients achieve less-than-expected benefit due to suboptimal weight loss (SWL) or weight regain (WR). Sub-optimal weight loss, defined as not achieving a weight loss of 40% to 60% of baseline excess body weight (EWL) over 1–2 years, occurs in about 11% to 22% of patients following bariatric surgery [33–38]. Conversely, weight regain, defined as initially achieving expected weight loss after surgery but regaining weight, has a much higher prevalence in the bariatric population and as such will be the focus of this review.

Weight Regain (WR) After Bariatric Surgery

Although the prevalence rates for WR vary depending on the weight parameters defining as "regain" [39], it is now well established that a large proportion of patients experience significant WR during long-term follow-up [33, 40–53]. In a study of 300 RYGB patients, 37% had significant weight regain at 7-year follow-up using the definition of ≥ 25% increase from nadir weight [50]. A systematic review revealed that up to 76% of SG patients had significant weight regain at 6-year follow-up [51]. In the largest prospective cohort study of 1406 RYGB patients, the average weight regain, as a percentage of nadir weight (lowest post-operative weight), was 5.7% at 1 year after reaching the nadir weight, increasing to 10.1% after 2 years, 12.9% after 3 years, 14.2% after 4 years, and 15% after 5 years, thus revealing that the largest change in weight regain occurs 2 years after reaching nadir weight, but continues for increase out to 5 years post-op [53••]. In the same study, the incidence of ≥10% weight regain was 23%, 51%, 64%, 69%, and 72% after 1 to 5 years respectively.

Causes of Weight Regain

While procedural failures such as slippage of the gastric band, gastro-gastric fistulas, dilated gastric fundus, and enlargement of the gastric pouch or gastro-jejunal stoma can result in weight regain [48, 51, 54–56], the most common causes are thought to be dysregulated (e.g., loss-of-control eating) or maladaptive (e.g., grazing) eating, noncompliance to dietary recommendations, return to previous eating habits, sedentary lifestyle, and physiological compensatory mechanisms such as changes in hormones that regulate energy intake leading to increased appetite and food cravings, and increased caloric intake [51, 57–69]. Comorbid psychiatric disorders, especially history of depression, have also been implicated as potential causes of treatment failure [70, 71].

Three maladaptive eating behaviors—grazing, loss-of-control eating, and binge eating—have been commonly reported among bariatric surgery patients. Grazing is described as uncontrolled, unplanned, repetitive eating of small amounts of food between mealtimes. In one study, more than of half of the patients who reported binge eating before surgery shifted to grazing behavior after surgery [60]. The prevalence of grazing behavior among post-bariatric surgery patients ranges from 17 to 47%, depending on the method of assessment, including structured interviews and/or validated questionnaires, and time after surgery [72, 73], and has been correlated with weight regain in several studies [63, 74–76]. Loss-of-control eating (LOCE) is a subjective perception of being compelled to eat, or unable to resist or stop eating, that leads to eating when not intended and/or difficulty stopping. It is often related to subjective distress [77] and has been associated with poorer outcomes including weight regain among post-bariatric surgery patients [78–84]. There is evidence of the increased prevalence of binge eating disorder (BED) among patients seeking bariatric surgery [80, 85, 86] which persists post-surgery and is associated with WR. However, because of their physical inability to rapidly eat large quantities of food in a short period of time [87, 88], post-bariatric surgery patients are unlikely to meet the binge eating threshold set by the Diagnostic and Statistical Manual of Mental Disorder, 5th edition (DSM-5). Nevertheless, an argument could be made that eating an amount of food that is unusually large for post-bariatric surgery patients might constitute a binge episode that is relevant to this population [89].

Predictors of Weight Regain

While several pre-operative patient characteristics have been found to be predictive of SWL after bariatric surgery [35, 37], there is a relative paucity for WR, with one study reporting that African American patients had greater post-operative weight regain than White or Hispanic patients [90]. Post-operative factors associated with weight regain include larger gastrojejunal stoma diameter, larger gastric volume following SG, longer post-operative follow-up, presence of diabetes, binge eating, LOCE, increased food urges, excessive nocturnal eating, lower physical activity, lower social support, life stresses, problematic alcohol use, and depressive symptoms [60, 72, 78–80, 83, 91–95]. Additionally, weight regain was associated with higher pre-prandial ghrelin and lower post-prandial GLP-1 levels although the data are limited [67, 68, 92].

Clinical Consequences of Weight Regain

Weight regain leads to the recurrence of obesity-related comorbidities including T2D, hypertension, and dyslipidemia, increases health care costs, and has a negative effect on the quality of life and emotional health [41, 96–101].

Therefore, it is imperative that adjunctive therapies with proven efficacy are available for optimal management of weight regain and to maximize the long-term benefits of surgery.

Interventions for Prevention of Weight Regain or to Improve Overall Outcomes

Barring two small (N = 18–30) studies [102, 103], nutritional, cognitive-behavioral, supportive, and other psychological and lifestyle interventions started at the time of bariatric surgery or up to 2 years post-operatively, have not demonstrated a significant effect on overall weight loss [104–112]. In a study that enrolled subjects who had bariatric surgery between 3 months and 8.5 years, weight changes after 12 weeks did not differ between those who received high-volume exercise intervention vs control group (4.2 kg vs 4.7 kg; P = 0.46) [113]. Systematic reviews and meta-analyses have concluded that these interventions have a marginal or no effect on post-operative weight loss or maintenance [114, 115].

Interventions for Reversal of Weight Regain

Revisional Surgery

Certain anatomical causes of weight regain after Roux-en-Y gastric bypass (i.e., pouch/stoma dilation, or gastro-gastric fistula) sleeve gastrectomy (i.e., antrum or fundus dilation) or gastric band can be corrected with revisional surgery. Indeed, while the evidence is based on retrospective cohort analyses, reversal of weight gain, as percent excess body mass index loss (%EBMIL) after RYGB ranges from 43.3–63.7% at 1 year, and 14–76% at 3 years post-revision, depending on the procedure employed [116]. Further, conversion of SG to RYGB for WR results in a 40% excess body weight loss (%EBWL) at 12 months [117], albeit this is based on 2 studies. Finally, %EBWL after conversion of the gastric band to either RYGB or SG ranged from 23 to 74 %, with a mean follow-up between 7.3 and 44.4 months [118]. However, since most revisional surgical procedures carry a higher morbidity than the primary procedures [119, 120], non-surgical interventions should be tried first [48].

Behavior Therapy/Lifestyle Interventions

In 3 small trials (N = 11 to 28) which specifically enrolled patients with WR after bariatric surgery, behavioral interventions resulted in weight loss ranging from 1.6 to 5.1% over 6–10 weeks, but the absence of control groups limits the interpretation of efficacy [121–123]. The largest study (n = 71) to date of behavior therapy for post-surgery WR reported no meaningful benefit for the therapy group vs the wait-listed control group (average weight change: −0.8% vs 0.3%) after 10 weeks [124].

A retrospective chart-review study noted that 44 patients with post-surgery WR who participated in lifestyle intervention without pharmacotherapy lost an average of 2.1 kg after an average duration of 14.7 months [125]. In a non-randomized study of surgical revision procedures and pharmacotherapy for reversal of WR, the control group given diet/lifestyle counseling achieved no weight loss (75 ± 15 kg baseline vs 76 ± 14 kg) at 1 year [126].

Finally, a 5-month supervised high-intensity exercise program led to a small average weight loss of 1.2 kg; however, at 2 months after the intervention ended, the subjects had an average 1.1 kg weight regain [127].

In summary, dietary, behavioral and exercise interventions have not demonstrated efficacy in reversing WR after bariatric surgery.

Pharmacotherapy

As shown in Table 1, published studies to date of pharmacotherapy for reversal of weight regain after bariatric surgery consisted of 8 retrospective studies and 2 open-label trials. Some studies also included patients for whom pharmacotherapy was believed to have been prescribed for SWL or weight-loss plateau to promote additional weight loss. Not included in Table 1 are publications reporting (a) pharmacotherapy specifically targeting SWL, or initiated around the time of bariatric surgery to boost overall weight loss, (b) sub-group analyses using the previously published data, (c) those reporting 'associations' between weight change and anti-obesity drug prescriptions via electronic medical record search without determining whether the prescriptions were aimed at SWL, prevention or reversal of WR, or to improve overall weight loss, and (d) publications not reporting the change of weight with treatment. Topiramate (TPM) and phentermine (PHEN) were the most prescribed drugs and there is limited evidence for the effectiveness of topiramate and liraglutide. As narrated in the 'Comments' section, these studies were limited by their retrospective data collection, lack of predetermined censoring of the beginning and end of data collection, lack of a priori hypotheses, lack of randomization, small sample sizes, lack of control group, unclear definitions of WR, insufficient or missing data, lack of safety data, improper interpretation of results, and generally poor quality of reporting.

Conclusions

Although bariatric surgery remains the most effective treatment for obesity leading to sustained weight loss and amelioration of most weight-related comorbidities, especially

Table 1 Published studies of pharmacotherapy for weight regain after bariatric surgery

Reference	Interventions	Design	*N*	Duration (months)	Weight loss	Comments
Jester et al. (1996) [128]	PHEN 15 mg FEN 20 mg PHEN/FEN 15/20	Prospective open-label	34	3	WL = 4.5 kg to 22.7 kg	Data collected in one private clinic. 20 of 34 completed 3 months. No information regarding how many were treated with each medication.
Pajecki et al. (2012) [129]	Liraglutide 1.2 mg–1.8 mg	Retrospective	15	2–7; avg 3	WL = 2 kg to 18 kg	40% experienced nausea. Included patients with SWL.
Schwartz et al. (2016) [130]	PHEN 37.5 mg PHEN/TPM 1200 kcal/d diet for all	Retrospective	65 (PHEN 52; PHEN/TPM 13)	3	PHEN group averaged 6.3kg WL.	Only 30 patients had assessment at 3 months (24 PHEN, 6 PHEN/TPM). Included patients reaching weight loss plateau. Very few treated with PHEN/TPM.
Stanford et al. (2017) [131]	PHEN TPM Zonisamide Metformin Bupropion Orlistat Sibutramine Liraglutide Exenatide Pramlintide Naltrexone Lorcaserin PHEN/TPM Canagliflozin BUP/Naltrexone	Retrospective EMR review	319 Prescribed at WR =249 Prescribed at weight plateau = 68	Variable, not reported	56% had ≥ 5% W Mean WL = 7.6%	TPM, PHEN, metformin, bupropion, and zonisamide were most frequently prescribed. TPM was reported as the only medication that was effective based on OR 1.9 (95% CI: 1.1, 3.2; $P = 0.02$) for achieving ≥ 10% weight loss. However, TPM was not effective for achieving ≥ 5% weight loss based on OR 1.03 (95% CI: 0.65, 1.64; $P = 0.90$). In fact, none of the medications were associated with a significant OR for achieving ≥ 5% weight loss. Unclear how the investigators determined whether the medications were prescribed at weight plateau or for reversal of WR, or for treating other conditions. For example, metformin, exenatide, pramlintide, liraglutide, and canagliflozin might have been prescribed for diabetes, topiramate for migraine, bupropion for depression, and naltrexone for alcohol or opiate use disorder. Weight loss was calculated as the difference between weight when medication was started and nadir weight at any timepoint during medication treatment. Ideally, weight change should be the difference between start and the end of treatment and not the difference between the start of treatment and maximum weight loss. This method of data extraction disregarded weight regain while the same medication was continued beyond the nadir weight loss, thus overestimating the treatment effect. No clear explanation of which medication the weight loss was credited to when subjects took several antiobesity medications on and off or had a new medication added. No information on dose or duration of antiobesity medication therapy.

Table 1 (continued)

Reference	Interventions	Design	*N*	Duration (months)	Weight loss	Comments
Nor Hanipah et al. (2018) [132]	PHEN PHEN/TPM Lorcaserin BUP/Naltrexone	Retrospective	209	12	Avg WL = 3.2% at 3 m, and 2.2% at 1 yr; 37% had 1 yr WL > 5%	PHEN (75%) and PHEN/TPM (12%) were the most frequently prescribed medications. Included patients with SWL.
Srivastava et al. (2018) [133]	Metformin PHEN TPM PHEN/TPM BUP/Naltrexone Lorcaserin Zonisamide GLP-1RAs	Retrospective	48	6	2.2% WL at 3 m; 4.2% WL at 6 m	High attrition rate of 37% at 3 months and 68% at 6 months. Greater weight loss in those taking 2 or more meds compared to only one med or no meds.
Rye et al. (2018) [134]	Liraglutide 3.0 mg	Retrospective	20	7	Median WL 7.1% at 16 wks and 9.7% at 28 wks	Small sample. Included patients with SWL.
Wharton et al. (2019) [125]	Liraglutide 3.0 mg	Retrospective	117	7.6 ± 7.1	Avg WL = 5.5%	Variable duration. 29% experienced nausea. Only 37% were taking liraglutide at 1 yr.
Horber et al. (2021) [126]	Liraglutide 3.0 mg (LG) Fobi Ring with pouch resizing (FP) Endosurgery (ES) Diet counseling (DC)	Prospective open-label	Total = 95 LG = 34 FP = 16 ES = 15 DC = 30	24	Ave WL Liraglutide = 12 kg FP = 17 kg DC = 0.0 kg	Single obesity clinic. Non-randomized. Self-selection bias. Treatments were paid by public health insurance. ES group had an average weight loss of 3 kg after 12 months at which time all patients demanded additional drug therapy. Hence, 24-month weight loss is not available for the ES group.
Gazda et al. (2021) [135]	Intensive Lifestyle Modification (ILM) Non-GLP-1RAs: orlistat, TPM, PHEN, PHEN/TPM, lisdexamfetamine, naltrexone, BUP/Naltrexone, lorcaserin GLP-1RAs: liraglutide, semaglutide, exenatide, dulaglutide, albiglutide, lixisenatide	Retrospective EMR review 6.1	Total = 207 3m = 201 6m = 112 9m = 67 12m = 53	3–12	Mean (SD) WL% At 3 m: ILM = 1.4 (4.1)% Non-GLP-1RAs = 2.2 (3.6)% GLP-1RAs = 4.5 (3.1)% $P < 0.001$ At 12 m: ILM = 2.4 (4.9)% Non-GLP-1RAs = 5.4 (15.8)% GLP-1RAs = 8.9 (7.2)% $P = 0.12$	Medications were added to ILM intervention. Unknown whether GLP-1RAs were prescribed for weight management or diabetes control. Total sample dropped from 207 at the start of treatment to 53 (10 each in ILM and non-GLP-1 groups, and 33 in GLP-1 group) at 12 m. Large variability in weight loss. The investigators did not perform individual chart reviews to determine reasons for treatment discontinuation which might have included change in health insurance, affordability, lack of efficacy, adverse events, change in treatment group, lost to follow-up, or censoring by cut-off date.

Table 1 (continued)

Reference	Interventions	Design	*N*	Duration (months)	Weight loss	Comments
Rubio et al. (2021) [136]	Liraglutide 3.0 mg	Prospective open-label	23	12	Mean (SD) WL% Daily dosing: 17.9 (6.1)% Alternate day dosing: 17.2 (5.0)%	36 non-diabetic patients with obesity who had bariatric surgery and regained weight were treated with daily liraglutide 3.0 mg s.c. During the first 12 weeks, 13 patients were excluded (lack of effectiveness = 8; voluntary withdrawal due to economic reasons = 5). Of the 23 patients who completed 6 months, 11 were switched to liraglutide 3.0 mg alternate day dosing and 12 continued daily liraglutide 3.0 mg. The average weight loss of 17.9% with daily liraglutide 3.0 mg was unusually large (twice as much as the average weight loss observed with daily liraglutide 3.0 mg in RCTs in patients with obesity who never had surgery). Exclusion of patients for lack of effectiveness during the first weeks, small sample size, open-label nature of treatment, and lack of adequate description of the ancillary treatments the patients received are notable limitations.

EMR electronic medical record, *BUP* bupropion, *FEN* fenfluramine, *GLP-1RA* glucagon-like peptide-1 receptor agonist, *PHEN* phentermine, *PHEN/FEN* phentermine+fenfluramine, *PHEN/TPM* phentermine+topiramate, *SWL* suboptimal weight loss, *TPM* topiramate, *WL* total weight loss

T2D, it is now well recognized that a large proportion of patients experience significant WR during long-term follow-up. The prevalence rates of WR vary widely depending on the definition and the time since surgery. While WR could be attributed to anatomic and surgical causes in a small percentage of cases, the major causes of WR seem to be postoperative increased caloric intake due to increased appetite and maladaptive or dysregulated eating, inadequate physical activity, and psychosocial stresses. Unfortunately, WR is associated with the recurrence of previously controlled T2D, hypertension, and other weight-related comorbidities, with lowered quality of life and emotional health. Prevention of WR would be ideal, but unfortunately, the behavioral and lifestyle interventions aimed at prevention have not demonstrated efficacy. For reversal of WR, revisional surgery can be effective in some cases but is generally associated with a higher rate of complications than primary bariatric surgery. Dietary, behavioral, and exercise interventions have demonstrated null or marginal efficacy in reversing WR. Published studies of pharmacotherapy for WR have been mostly retrospective reviews of medical records or small open-label trials, and it appears that antiobesity drugs induce less weight loss in patients with a history of bariatric surgery than those without. There is a dire need for demonstration of efficacy in RCTs for cost-effective pharmacotherapy combined with lifestyle modification for the management of weight regain after bariatric surgery.

Funding This work was supported by a grant (R01 DK129936) from the National Institute of Diabetes and Digestive and Kidney Diseases (K.M.G).

Declarations

Conflict of Interest Kishore M. Gadde reports grants to his institution from AstraZeneca, BioKier, Indiana University Foundation, and National Institutes of Health, outside the submitted work. Ninh T Nguyen receives honorarium as a speaker from Olympus and Endogastric Solutions.

Human and Animal Rights This is a review article which reports previously published studies with human subjects. No animal experiments are reported in this article.

References

Papers of particular interest, published recently, have been highlighted as:
•• Of major importance

1. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017-2018. NCHS Data Brief. 2020;360:1–8.
2. Ward ZJ, Bleich SN, Cradock AL, Barrett JL, Giles CM, Flax C, et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381(25):2440–50. https://doi.org/10.1056/NEJMsa1909301.
3. Gadde KM, Martin CK, Berthoud HR, Heymsfield SB. Obesity: pathophysiology and management. J Am Coll Cardiol. 2018;71(1):69–84. https://doi.org/10.1016/j.jacc.2017.11.011.
4. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–9. https://doi.org/10.1001/jama.2020.6775.
5. Tamara A, Tahapary DL. Obesity as a predictor for a poor prognosis of COVID-19: a systematic review. Diabetes Metab Syndr. 2020;14(4):655–9. https://doi.org/10.1016/j.dsx.2020.05.020.
6. Kompaniyets L, Goodman AB, Belay B, Freedman DS, Sucosky MS, Lange SJ, et al. Body mass index and risk for COVID-19-related hospitalization, intensive care unit admission, invasive mechanical ventilation, and death - United States, March-December 2020. MMWR Morb Mortal Wkly Rep. 2021;70(10):355–61. https://doi.org/10.15585/mmwr.mm7010e4.
7. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):S102–38. https://doi.org/10.1161/01.cir.0000437739.71477.ee.
8. Douketis JD, Macie C, Thabane L, Williamson DF. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond). 2005;29(10):1153–67. https://doi.org/10.1038/sj.ijo.0802982.
9. Dombrowski SU, Knittle K, Avenell A, Araújo-Soares V, Sniehotta FF. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. BMJ. 2014;348:g2646. https://doi.org/10.1136/bmj.g2646.
10. Coughlin JW, Brantley PJ, Champagne CM, Vollmer WM, Stevens VJ, Funk K, et al. The impact of continued intervention on weight: five-year results from the weight loss maintenance trial. Obesity (Silver Spring). 2016;24(5):1046–53. https://doi.org/10.1002/oby.21454.
11. Venditti EM, Bray GA, Carrion-Petersen ML, Delahanty LM, Edelstein SL, Hamman RF, et al. First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes. Int J Obes (Lond). 2008;32(10):1537–44. https://doi.org/10.1038/ijo.2008.134.
12. Gadde KM, Pritham RY. Pharmacotherapy of obesity: clinical trials to clinical practice. Curr Diab Rep. 2017;17(5):34. https://doi.org/10.1007/s11892-017-0859-2.
13. Shi Q, Wang Y, Hao Q, Vandvik PO, Guyatt G, Li J, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2022;399(10321):259–69. https://doi.org/10.1016/s0140-6736(21)01640-8.
14. Adams TD, Davidson LE, Litwin SE, Kim J, Kolotkin RL, Nanjee MN, et al. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med. 2017;377(12):1143–55. https://doi.org/10.1056/NEJMoa1700459.
15. Maciejewski ML, Arterburn DE, Van Scoyoc L, Smith VA, Yancy WS Jr, Weidenbacher HJ, et al. Bariatric surgery and long-term durability of weight loss. JAMA Surg. 2016;151(11):1046–55. https://doi.org/10.1001/jamasurg.2016.2317.

16. Arterburn DE, Telem DA, Kushner RF, Courcoulas AP. Benefits and risks of bariatric surgery in adults: a review. JAMA. 2020;324(9):879–87. https://doi.org/10.1001/jama.2020.12567.
17. Sheng B, Truong K, Spitler H, Zhang L, Tong X, Chen L. The long-term effects of bariatric surgery on type 2 diabetes remission, microvascular and macrovascular complications, and mortality: a systematic review and meta-analysis. Obes Surg. 2017;27(10):2724–32. https://doi.org/10.1007/s11695-017-2866-4.
18. Carlsson LM, Peltonen M, Ahlin S, Anveden Å, Bouchard C, Carlsson B, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012;367(8):695–704. https://doi.org/10.1056/NEJMoa1112082.
19. Sjöström L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden Å, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311(22):2297–304. https://doi.org/10.1001/jama.2014.5988.
20. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Capristo E, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2021;397(10271):293–304. https://doi.org/10.1016/s0140-6736(20)32649-0.
21. Jakobsen GS, Småstuen MC, Sandbu R, Nordstrand N, Hofsø D, Lindberg M, et al. Association of bariatric surgery vs medical obesity treatment with long-term medical complications and obesity-related comorbidities. JAMA. 2018;319(3):291–301. https://doi.org/10.1001/jama.2017.21055.
22. Schiavon CA, Bersch-Ferreira AC, Santucci EV, Oliveira JD, Torreglosa CR, Bueno PT, et al. Effects of bariatric surgery in obese patients with hypertension: The GATEWAY Randomized Trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension). Circulation. 2018;137(11):1132–42. https://doi.org/10.1161/circulationaha.117.032130.
23. Heffron SP, Parikh A, Volodarskiy A, Ren-Fielding C, Schwartzbard A, Nicholson J, et al. Changes in lipid profile of obese patients following contemporary bariatric surgery: a meta-analysis. Am J Med. 2016;129(9):952–9. https://doi.org/10.1016/j.amjmed.2016.02.004.
24. Aminian A, Zajichek A, Arterburn DE, Wolski KE, Brethauer SA, Schauer PR, et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA. 2019;322(13):1271–82. https://doi.org/10.1001/jama.2019.14231.
25. Moussa O, Ardissino M, Heaton T, Tang A, Khan O, Ziprin P, et al. Effect of bariatric surgery on long-term cardiovascular outcomes: a nationwide nested cohort study. Eur Heart J. 2020;41(28):2660–7. https://doi.org/10.1093/eurheartj/ehaa069.
26. Näslund E, Stenberg E, Hofmann R, Ottosson J, Sundbom M, Marsk R, et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with previous myocardial infarction and severe obesity: a nationwide cohort study. Circulation. 2021;143(15):1458–67. https://doi.org/10.1161/circulationaha.120.048585.
27. Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307(1):56–65. https://doi.org/10.1001/jama.2011.1914.
28. Reges O, Greenland P, Dicker D, Leibowitz M, Hoshen M, Gofer I, et al. Association of bariatric surgery using laparoscopic banding, Roux-en-Y gastric bypass, or laparoscopic sleeve gastrectomy vs usual care obesity management with all-cause mortality. JAMA. 2018;319(3):279–90. https://doi.org/10.1001/jama.2017.20513.
29. Carlsson LMS, Sjöholm K, Jacobson P, Andersson-Assarsson JC, Svensson PA, Taube M, et al. Life expectancy after bariatric surgery in the Swedish obese subjects study. N Engl J Med. 2020;383(16):1535–43. https://doi.org/10.1056/NEJMoa2002449.
30. Wiggins T, Guidozzi N, Welbourn R, Ahmed AR, Markar SR. Association of bariatric surgery with all-cause mortality and incidence of obesity-related disease at a population level: a systematic review and meta-analysis. PLoS Med. 2020;17(7):e1003206. https://doi.org/10.1371/journal.pmed.1003206.
31. Syn NL, Cummings DE, Wang LZ, Lin DJ, Zhao JJ, Loh M, et al. Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants. Lancet. 2021;397(10287):1830–41. https://doi.org/10.1016/s0140-6736(21)00591-2.
32. American Society for Metabolic and Bariatric Surgery. Estimate of bariatric surgery numbers, 2011-2019. https://asmbs.org/resources/estimate-of-bariatric-surgery-numbers. https://asmbs.org/resources/estimate-of-bariatric-surgery-numbers. Accessed 30 June 2021.
33. Wittgrove AC, Clark GW. Laparoscopic gastric bypass, Roux-en-Y- 500 patients: technique and results, with 3-60 month follow-up. Obes Surg. 2000;10(3):233–9. https://doi.org/10.1381/096089200321643511.
34. Ma Y, Pagoto SL, Olendzki BC, Hafner AR, Perugini RA, Mason R, et al. Predictors of weight status following laparoscopic gastric bypass. Obes Surg. 2006;16(9):1227–31. https://doi.org/10.1381/096089206778392284.
35. Melton GB, Steele KE, Schweitzer MA, Lidor AO, Magnuson TH. Suboptimal weight loss after gastric bypass surgery: correlation of demographics, comorbidities, and insurance status with outcomes. J Gastrointest Surg. 2008;12(2):250–5. https://doi.org/10.1007/s11605-007-0427-1.
36. Campos GM, Rabl C, Mulligan K, Posselt A, Rogers SJ, Westphalen AC, et al. Factors associated with weight loss after gastric bypass. Arch Surg. 2008;143(9):877–83. https://doi.org/10.1001/archsurg.143.9.877.
37. Ortega E, Morínigo R, Flores L, Moize V, Rios M, Lacy AM, et al. Predictive factors of excess body weight loss 1 year after laparoscopic bariatric surgery. Surg Endosc. 2012;26(6):1744–50. https://doi.org/10.1007/s00464-011-2104-4.
38. Perugini RA, Mason R, Czerniach DR, Novitsky YW, Baker S, Litwin DE, et al. Predictors of complication and suboptimal weight loss after laparoscopic Roux-en-Y gastric bypass: a series of 188 patients. Arch Surg. 2003;138(5):541–5. https://doi.org/10.1001/archsurg.138.5.541.
39. Lauti M, Lemanu D, Zeng ISL, Su'a B, Hill AG, MacCormick AD. Definition determines weight regain outcomes after sleeve gastrectomy. Surg Obes Relat Dis. 2017;13(7):1123–9. https://doi.org/10.1016/j.soard.2017.02.029.
40. Sjöström CD, Lissner L, Wedel H, Sjöström L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res. 1999;7(5):477–84. https://doi.org/10.1002/j.1550-8528.1999.tb00436.x.
41. Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–93. https://doi.org/10.1056/NEJMoa035622.
42. Gumbs AA, Gagner M, Dakin G, Pomp A. Sleeve gastrectomy for morbid obesity. Obes Surg. 2007;17(7):962–9. https://doi.org/10.1007/s11695-007-9151-x.

43. Meguid MM, Glade MJ, Middleton FA. Weight regain after Roux-en-Y: a significant 20% complication related to PYY. Nutrition. 2008;24(9):832–42. https://doi.org/10.1016/j.nut.2008.06.027.
44. Magro DO, Geloneze B, Delfini R, Pareja BC, Callejas F, Pareja JC. Long-term weight regain after gastric bypass: a 5-year prospective study. Obes Surg. 2008;18(6):648–51. https://doi.org/10.1007/s11695-007-9265-1.
45. Himpens J, Dobbeleir J, Peeters G. Long-term results of laparoscopic sleeve gastrectomy for obesity. Ann Surg. 2010;252(2):319–24. https://doi.org/10.1097/SLA.0b013e3181e90b31.
46. Sarela AI, Dexter SP, O'Kane M, Menon A, McMahon MJ. Long-term follow-up after laparoscopic sleeve gastrectomy: 8-9-year results. Surg Obes Relat Dis. 2012;8(6):679–84. https://doi.org/10.1016/j.soard.2011.06.020.
47. Courcoulas AP, Christian NJ, Belle SH, Berk PD, Flum DR, Garcia L, et al. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA. 2013;310(22):2416–25. https://doi.org/10.1001/jama.2013.280928.
48. Karmali S, Brar B, Shi X, Sharma AM, de Gara C, Birch DW. Weight recidivism post-bariatric surgery: a systematic review. Obes Surg. 2013;23(11):1922–33. https://doi.org/10.1007/s11695-013-1070-4.
49. Lemanu DP, Singh PP, Rahman H, Hill AG, Babor R, MacCormick AD. Five-year results after laparoscopic sleeve gastrectomy: a prospective study. Surg Obes Relat Dis. 2015;11(3):518–24. https://doi.org/10.1016/j.soard.2014.08.019.
50. Cooper TC, Simmons EB, Webb K, Burns JL, Kushner RF. Trends in weight regain following Roux-en-Y gastric bypass (RYGB) bariatric surgery. Obes Surg. 2015;25(8):1474–81. https://doi.org/10.1007/s11695-014-1560-z.
51. Lauti M, Kularatna M, Hill AG, MacCormick AD. Weight regain following sleeve gastrectomy-a systematic review. Obes Surg. 2016;26(6):1326–34. https://doi.org/10.1007/s11695-016-2152-x.
52. Felsenreich DM, Langer FB, Kefurt R, Panhofer P, Schermann M, Beckerhinn P, et al. Weight loss, weight regain, and conversions to Roux-en-Y gastric bypass: 10-year results of laparoscopic sleeve gastrectomy. Surg Obes Relat Dis. 2016;12(9):1655–62. https://doi.org/10.1016/j.soard.2016.02.021.
53.•• King WC, Hinerman AS, Belle SH, Wahed AS, Courcoulas AP. Comparison of the performance of common measures of weight regain after bariatric surgery for association with clinical outcomes. JAMA. 2018;320(15):1560–9. https://doi.org/10.1001/jama.2018.14433 **This was the largest and longest prospective study that systematically assessed weight regain after bariatric surgery and its relationship to progression of diabetes, hyperlipidemia, and hypertension, and declines in qualify of life.**
54. Suter M. Laparoscopic band repositioning for pouch dilatation/slippage after gastric banding: disappointing results. Obes Surg. 2001;11(4):507–12. https://doi.org/10.1381/096089201321209431.
55. Yimcharoen P, Heneghan HM, Singh M, Brethauer S, Schauer P, Rogula T, et al. Endoscopic findings and outcomes of revisional procedures for patients with weight recidivism after gastric bypass. Surg Endosc. 2011;25(10):3345–52. https://doi.org/10.1007/s00464-011-1723-0.
56. Heneghan HM, Yimcharoen P, Brethauer SA, Kroh M, Chand B. Influence of pouch and stoma size on weight loss after gastric bypass. Surg Obes Relat Dis. 2012;8(4):408–15. https://doi.org/10.1016/j.soard.2011.09.010.
57. Hsu LK, Benotti PN, Dwyer J, Roberts SB, Saltzman E, Shikora S, et al. Nonsurgical factors that influence the outcome of bariatric surgery: a review. Psychosom Med. 1998;60(3):338–46. https://doi.org/10.1097/00006842-199805000-00021.
58. Rudolph A, Hilbert A. Post-operative behavioural management in bariatric surgery: a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2013;14(4):292–302. https://doi.org/10.1111/obr.12013.
59. Sarwer DB, Wadden TA, Fabricatore AN. Psychosocial and behavioral aspects of bariatric surgery. Obes Res. 2005;13(4):639–48. https://doi.org/10.1038/oby.2005.71.
60. Colles SL, Dixon JB, O'Brien PE. Grazing and loss of control related to eating: two high-risk factors following bariatric surgery. Obesity (Silver Spring). 2008;16(3):615–22. https://doi.org/10.1038/oby.2007.101.
61. Sarwer DB, Dilks RJ, West-Smith L. Dietary intake and eating behavior after bariatric surgery: threats to weight loss maintenance and strategies for success. Surg Obes Relat Dis. 2011;7(5):644–51. https://doi.org/10.1016/j.soard.2011.06.016.
62. Kruseman M, Leimgruber A, Zumbach F, Golay A. Dietary, weight, and psychological changes among patients with obesity, 8 years after gastric bypass. J Am Diet Assoc. 2010;110(4):527–34. https://doi.org/10.1016/j.jada.2009.12.028.
63. Kofman MD, Lent MR, Swencionis C. Maladaptive eating patterns, quality of life, and weight outcomes following gastric bypass: results of an Internet survey. Obesity (Silver Spring). 2010;18(10):1938–43. https://doi.org/10.1038/oby.2010.27.
64. Münzberg H, Laque A, Yu S, Rezai-Zadeh K, Berthoud HR. Appetite and body weight regulation after bariatric surgery. Obes Rev. 2015;16 Suppl 1(Suppl 1):77–90. https://doi.org/10.1111/obr.12258.
65. Yanos BR, Saules KK, Schuh LM, Sogg S. Predictors of lowest weight and long-term weight regain among Roux-en-Y gastric bypass patients. Obes Surg. 2015;25(8):1364–70. https://doi.org/10.1007/s11695-014-1536-z.
66. Sarwer DB, Fabricatore AN, Jones-Corneille LR, Allison KC, Faulconbridge LN, Wadden TA. Psychological issues following bariatric surgery. Primary Psychiatry. 2008;15(8):50–5.
67. Tamboli RA, Breitman I, Marks-Shulman PA, Jabbour K, Melvin W, Williams B, et al. Early weight regain after gastric bypass does not affect insulin sensitivity but is associated with elevated ghrelin. Obesity (Silver Spring). 2014;22(7):1617–22. https://doi.org/10.1002/oby.20776.
68. Santo MA, Riccioppo D, Pajecki D, Kawamoto F, de Cleva R, Antonangelo L, et al. Weight regain after gastric bypass: influence of gut hormones. Obes Surg. 2016;26(5):919–25. https://doi.org/10.1007/s11695-015-1908-z.
69. Amundsen T, Strømmen M, Martins C. Suboptimal weight loss and weight regain after gastric bypass surgery-postoperative status of energy intake, eating behavior, physical activity, and psychometrics. Obes Surg. 2017;27(5):1316–23. https://doi.org/10.1007/s11695-016-2475-7.
70. Kalarchian MA, Marcus MD, Levine MD, Soulakova JN, Courcoulas AP, Wisinski MS. Relationship of psychiatric disorders to 6-month outcomes after gastric bypass. Surg Obes Relat Dis. 2008;4(4):544–9. https://doi.org/10.1016/j.soard.2008.03.003.
71. Semanscin-Doerr DA, Windover A, Ashton K, Heinberg LJ. Mood disorders in laparoscopic sleeve gastrectomy patients: does it affect early weight loss? Surg Obes Relat Dis. 2010;6(2):191–6. https://doi.org/10.1016/j.soard.2009.11.017.
72. Pizato N, Botelho PB, Gonçalves VSS, Dutra ES, de Carvalho KMB. Effect of grazing behavior on weight regain post-bariatric surgery: a systematic review. Nutrients. 2017;9(12). https://doi.org/10.3390/nu9121322.
73. Conceição EM, Mitchell JE, Engel SG, Machado PP, Lancaster K, Wonderlich SA. What is "grazing"? Reviewing its

definition, frequency, clinical characteristics, and impact on bariatric surgery outcomes, and proposing a standardized definition. Surg Obes Relat Dis. 2014;10(5):973–82. https://doi.org/10.1016/j.soard.2014.05.002.
74. Conceição E, Mitchell JE, Vaz AR, Bastos AP, Ramalho S, Silva C, et al. The presence of maladaptive eating behaviors after bariatric surgery in a cross sectional study: importance of picking or nibbling on weight regain. Eat Behav. 2014;15(4):558–62. https://doi.org/10.1016/j.eatbeh.2014.08.010.
75. Conceição EM, Mitchell JE, Machado PPP, Vaz AR, Pinto-Bastos A, Ramalho S, et al. Repetitive eating questionnaire [Rep (eat)-Q]: Enlightening the concept of grazing and psychometric properties in a Portuguese sample. Appetite. 2017;117:351–8. https://doi.org/10.1016/j.appet.2017.07.012.
76. Nicolau J, Ayala L, Rivera R, Speranskaya A, Sanchís P, Julian X, et al. Postoperative grazing as a risk factor for negative outcomes after bariatric surgery. Eat Behav. 2015;18:147–50. https://doi.org/10.1016/j.eatbeh.2015.05.008.
77. Latner JD, Mond JM, Kelly MC, Haynes SN, Hay PJ. The loss of control over eating scale: development and psychometric evaluation. Int J Eat Disord. 2014;47(6):647–59. https://doi.org/10.1002/eat.22296.
78. White MA, Kalarchian MA, Masheb RM, Marcus MD, Grilo CM. Loss of control over eating predicts outcomes in bariatric surgery patients: a prospective, 24-month follow-up study. J Clin Psychiatry. 2010;71(2):175–84. https://doi.org/10.4088/JCP.08m04328blu.
79. Conceição E, Bastos AP, Brandão I, Vaz AR, Ramalho S, Arrojado F, et al. Loss of control eating and weight outcomes after bariatric surgery: a study with a Portuguese sample. Eat Weight Disord. 2014;19(1):103–9. https://doi.org/10.1007/s40519-013-0069-0.
80. Meany G, Conceição E, Mitchell JE. Binge eating, binge eating disorder and loss of control eating: effects on weight outcomes after bariatric surgery. Eur Eat Disord Rev. 2014;22(2):87–91. https://doi.org/10.1002/erv.2273.
81. Mitchell JE, Christian NJ, Flum DR, Pomp A, Pories WJ, Wolfe BM, et al. Postoperative behavioral variables and weight change 3 years after bariatric surgery. JAMA Surg. 2016;151(8):752–7. https://doi.org/10.1001/jamasurg.2016.0395.
82. Ivezaj V, Kessler EE, Lydecker JA, Barnes RD, White MA, Grilo CM. Loss-of-control eating following sleeve gastrectomy surgery. Surg Obes Relat Dis. 2017;13(3):392–8. https://doi.org/10.1016/j.soard.2016.09.028.
83. Devlin MJ, King WC, Kalarchian MA, Hinerman A, Marcus MD, Yanovski SZ, et al. Eating pathology and associations with long-term changes in weight and quality of life in the longitudinal assessment of bariatric surgery study. Int J Eat Disord. 2018;51(12):1322–30. https://doi.org/10.1002/eat.22979.
84. Smith KE, Orcutt M, Steffen KJ, Crosby RD, Cao L, Garcia L, et al. Loss of control eating and binge eating in the 7 years following bariatric surgery. Obes Surg. 2019;29(6):1773–80. https://doi.org/10.1007/s11695-019-03791-x.
85. Niego SH, Kofman MD, Weiss JJ, Geliebter A. Binge eating in the bariatric surgery population: a review of the literature. Int J Eat Disord. 2007;40(4):349–59. https://doi.org/10.1002/eat.20376.
86. Grupski AE, Hood MM, Hall BJ, Azarbad L, Fitzpatrick SL, Corsica JA. Examining the Binge Eating Scale in screening for binge eating disorder in bariatric surgery candidates. Obes Surg. 2013;23(1):1–6. https://doi.org/10.1007/s11695-011-0537-4.
87. Powers PS, Perez A, Boyd F, Rosemurgy A. Eating pathology before and after bariatric surgery: a prospective study. Int J Eat Disord. 1999;25(3):293–300. https://doi.org/10.1002/(sici)1098-108x(199904)25:3<293::aid-eat7>3.0.co;2-g.
88. Dymek MP, le Grange D, Neven K, Alverdy J. Quality of life and psychosocial adjustment in patients after Roux-en-Y gastric bypass: a brief report. Obes Surg. 2001;11(1):32–9. https://doi.org/10.1381/096089201321454088.
89. Ivezaj V, Lydecker JA, Wiedemann AA, Duffy AJ, Grilo CM. Does Bariatric Binge-eating size matter? Conceptual model and empirical support. Obesity (Silver Spring). 2020;28(9):1645–51. https://doi.org/10.1002/oby.22876.
90. Thomas DD, Anderson WA, Apovian CM, Hess DT, Yu L, Velazquez A, et al. Weight recidivism after Roux-en-Y gastric bypass surgery: an 11-year experience in a multiethnic medical center. obesity. 2019;27(2):217–25. https://doi.org/10.1002/oby.22360.
91. Yanos BR, Saules KK, Schuh LM, Sogg S. Predictors of lowest weight and long-term weight regain among Roux-en-Y gastric bypass patients. Obesity Surgery. 2015;25(8):1364–70. https://doi.org/10.1007/s11695-014-1536-z.
92. Athanasiadis DI, Martin A, Kapsampelis P, Monfared S, Stefanidis D. Factors associated with weight regain post-bariatric surgery: a systematic review. Surg Endosc. 2021;35(8):4069–84. https://doi.org/10.1007/s00464-021-08329-w.
93. Odom J, Zalesin KC, Washington TL, Miller WW, Hakmeh B, Zaremba DL, et al. Behavioral predictors of weight regain after bariatric surgery. Obes Surg. 2010;20(3):349–56. https://doi.org/10.1007/s11695-009-9895-6.
94. Belligoli A, Bettini S, Segato G, Busetto L. Predicting responses to bariatric and metabolic surgery. Curr Obes Rep. 2020;9(3):373–9. https://doi.org/10.1007/s13679-020-00390-1.
95. White MA, Kalarchian MA, Levine MD, Masheb RM, Marcus MD, Grilo CM. Prognostic significance of depressive symptoms on weight loss and psychosocial outcomes following gastric bypass surgery: a prospective 24-month follow-up study. Obes Surg. 2015;25(10):1909–16. https://doi.org/10.1007/s11695-015-1631-9.
96. Shah M, Simha V, Garg A. Review: long-term impact of bariatric surgery on body weight, comorbidities, and nutritional status. J Clin Endocrinol Metab. 2006;91(11):4223–31. https://doi.org/10.1210/jc.2006-0557.
97. DiGiorgi M, Rosen DJ, Choi JJ, Milone L, Schrope B, Olivero-Rivera L, et al. Re-emergence of diabetes after gastric bypass in patients with mid- to long-term follow-up. Surg Obes Relat Dis. 2010;6(3):249–53. https://doi.org/10.1016/j.soard.2009.09.019.
98. Jiménez A, Casamitjana R, Flores L, Viaplana J, Corcelles R, Lacy A, et al. Long-term effects of sleeve gastrectomy and Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus in morbidly obese subjects. Ann Surg. 2012;256(6):1023–9. https://doi.org/10.1097/SLA.0b013e318262ee6b.
99. Sheppard CE, Lester EL, Chuck AW, Birch DW, Karmali S, de Gara CJ. The economic impact of weight regain. Gastroenterol Res Pract. 2013;2013:379564. https://doi.org/10.1155/2013/379564.
100. Karlsson J, Taft C, Rydén A, Sjöström L, Sullivan M. Ten-year trends in health-related quality of life after surgical and conventional treatment for severe obesity: the SOS intervention study. Int J Obes (Lond). 2007;31(8):1248–61. https://doi.org/10.1038/sj.ijo.0803573.
101. Jirapinyo P, Abu Dayyeh BK, Thompson CC. Weight regain after Roux-en-Y gastric bypass has a large negative impact on the Bariatric Quality of Life Index. BMJ Open Gastroenterol. 2017;4(1):e000153. https://doi.org/10.1136/bmjgast-2017-000153.
102. Papalazarou A, Yannakoulia M, Kavouras SA, Komesidou V, Dimitriadis G, Papakonstantinou A, et al. Lifestyle intervention favorably affects weight loss and maintenance following obesity surgery. Obesity (Silver Spring). 2010;18(7):1348–53. https://doi.org/10.1038/oby.2009.346.

103. Kalarchian MA, Marcus MD, Courcoulas AP, Lutz C, Cheng Y, Sweeny G. Structured dietary intervention to facilitate weight loss after bariatric surgery: a randomized, controlled pilot study. Obesity (Silver Spring). 2016;24(9):1906–12. https://doi.org/10.1002/oby.21591.
104. Swenson BR, Saalwachter Schulman A, Edwards MJ, Gross MP, Hedrick TL, Weltman AL, et al. The effect of a low-carbohydrate, high-protein diet on post laparoscopic gastric bypass weight loss: a prospective randomized trial. J Surg Res. 2007;142(2):308–13. https://doi.org/10.1016/j.jss.2007.02.052.
105. Nijamkin MP, Campa A, Sosa J, Baum M, Himburg S, Johnson P. Comprehensive nutrition and lifestyle education improves weight loss and physical activity in Hispanic Americans following gastric bypass surgery: a randomized controlled trial. J Acad Nutr Diet. 2012;112(3):382–90. https://doi.org/10.1016/j.jada.2011.10.023.
106. Lier H, Biringer E, Stubhaug B, Tangen T. The impact of preoperative counseling on postoperative treatment adherence in bariatric surgery patients: a randomized controlled trial. Patient Educ Couns. 2012;87(3):336–42. https://doi.org/10.1016/j.pec.2011.09.014.
107. Wild B, Hünnemeyer K, Sauer H, Hain B, Mack I, Schellberg D, et al. A 1-year videoconferencing-based psychoeducational group intervention following bariatric surgery: results of a randomized controlled study. Surg Obes Relat Dis. 2015;11(6):1349–60. https://doi.org/10.1016/j.soard.2015.05.018.
108. Ogden J, Hollywood A, Pring C. The impact of psychological support on weight loss post weight loss surgery: a randomised control trial. Obes Surg. 2015;25(3):500–5. https://doi.org/10.1007/s11695-014-1428-2.
109. Chacko SA, Yeh GY, Davis RB, Wee CC. A mindfulness-based intervention to control weight after bariatric surgery: preliminary results from a randomized controlled pilot trial. Complement Ther Med. 2016;28:13–21. https://doi.org/10.1016/j.ctim.2016.07.001.
110. Hanvold SE, Vinknes KJ, Løken EB, Hjartåker A, Klungsøyr O, Birkeland E, et al. Does lifestyle intervention after gastric bypass surgery prevent weight regain? A randomized clinical trial. Obes Surg. 2019;29(11):3419–31. https://doi.org/10.1007/s11695-019-04109-7.
111. Paul L, van der Heiden C, van Hoeken D, Deen M, Vlijm A, Klaassen RA, et al. Cognitive behavioral therapy versus usual care before bariatric surgery: one-year follow-up results of a randomized controlled trial. Obes Surg. 2021;31(3):970–9. https://doi.org/10.1007/s11695-020-05081-3.
112. Lauti M, Kularatna M, Pillai A, Hill AG, MacCormick AD. A randomised trial of text message support for reducing weight regain following sleeve gastrectomy. Obes Surg. 2018;28(8):2178–86. https://doi.org/10.1007/s11695-018-3176-1.
113. Shah M, Snell PG, Rao S, Adams-Huet B, Quittner C, Livingston EH, et al. High-volume exercise program in obese bariatric surgery patients: a randomized, controlled trial. Obesity (Silver Spring). 2011;19(9):1826–34. https://doi.org/10.1038/oby.2011.172.
114. Beck NN, Johannsen M, Støving RK, Mehlsen M, Zachariae R. Do postoperative psychotherapeutic interventions and support groups influence weight loss following bariatric surgery? A systematic review and meta-analysis of randomized and non-randomized trials. Obes Surg. 2012;22(11):1790–7. https://doi.org/10.1007/s11695-012-0739-4.
115. Stewart F, Avenell A. Behavioural interventions for severe obesity before and/or after bariatric surgery: a systematic review and meta-analysis. Obes Surg. 2016;26(6):1203–14. https://doi.org/10.1007/s11695-015-1873-6.
116. Tran DD, Nwokeabia ID, Purnell S, Zafar SN, Ortega G, Hughes K, et al. Revision of Roux-En-Y gastric bypass for weight regain: a systematic review of techniques and outcomes. Obes Surg. 2016;26(7):1627–34. https://doi.org/10.1007/s11695-016-2201-5.
117. Matar R, Monzer N, Jaruvongvanich V, Abusaleh R, Vargas EJ, Maselli DB, et al. Indications and outcomes of conversion of sleeve gastrectomy to Roux-en-Y gastric bypass: a systematic review and a meta-analysis. Obes Surg. 2021;31(9):3936–46. https://doi.org/10.1007/s11695-021-05463-1.
118. Coblijn UK, Verveld CJ, van Wagensveld BA, Lagarde SM. Laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy as revisional procedure after adjustable gastric band--a systematic review. Obes Surg. 2013;23(11):1899–914. https://doi.org/10.1007/s11695-013-1058-0.
119. Brethauer SA, Kothari S, Sudan R, Williams B, English WJ, Brengman M, et al. Systematic review on reoperative bariatric surgery: American Society for Metabolic and Bariatric Surgery Revision Task Force. Surg Obes Relat Dis. 2014;10(5):952–72. https://doi.org/10.1016/j.soard.2014.02.014.
120. Inabnet WB 3rd, Belle SH, Bessler M, Courcoulas A, Dellinger P, Garcia L, et al. Comparison of 30-day outcomes after non-LapBand primary and revisional bariatric surgical procedures from the Longitudinal Assessment of Bariatric Surgery study. Surg Obes Relat Dis. 2010;6(1):22–30. https://doi.org/10.1016/j.soard.2009.10.007.
121. Himes SM, Grothe KB, Clark MM, Swain JM, Collazo-Clavell ML, Sarr MG. Stop regain: a pilot psychological intervention for bariatric patients experiencing weight regain. Obes Surg. 2015;25(5):922–7. https://doi.org/10.1007/s11695-015-1611-0.
122. Bradley LE, Forman EM, Kerrigan SG, Butryn ML, Herbert JD, Sarwer DB. A pilot study of an acceptance-based behavioral intervention for weight regain after bariatric surgery. Obes Surg. 2016;26(10):2433–41. https://doi.org/10.1007/s11695-016-2125-0.
123. Bradley LE, Forman EM, Kerrigan SG, Goldstein SP, Butryn ML, Thomas JG, et al. Project HELP: a remotely delivered behavioral intervention for weight regain after bariatric surgery. Obes Surg. 2017;27(3):586–98. https://doi.org/10.1007/s11695-016-2337-3.
124. Bradley L, Kelly M, Corsica J, Hood M, Smith-Mason C. Project HELP: a randomized controlled trial evaluating the effect of a remotely-delivered acceptance-based behavioral intervention for reducing postoperative weight regain. Surg Obes Relat Dis. 2019;15:S97. https://doi.org/10.1016/j.soard.2019.08.206.
125. Wharton S, Kuk JL, Luszczynski M, Kamran E, Christensen RAG. Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery. Clin Obes. 2019;9(4):e12323. https://doi.org/10.1111/cob.12323.
126. Horber FF, Steffen R. Reversal of long-term weight regain after Roux-en-Y gastric bypass using liraglutide or surgical revision. A prospective study. Obes Surg. 2021;31(1):93–100. https://doi.org/10.1007/s11695-020-04856-y.
127. Marc-Hernández A, Ruiz-Tovar J, Aracil A, Guillén S, Moya-Ramón M. Effects of a high-intensity exercise program on weight regain and cardio-metabolic profile after 3 years of bariatric surgery: a randomized trial. Sci Rep. 2020;10(1):3123. https://doi.org/10.1038/s41598-020-60044-z.
128. Jester L, Wittgrove AC, Clark W. Adjunctive use of appetite suppressant medications for improved weight management in bariatric surgical patients. Obes Surg. 1996;6(5):412–5. https://doi.org/10.1381/096089296765556476.
129. Pajecki D, Halpern A, Cercato C, Mancini M, de Cleva R, Santo MA. Short-term use of liraglutide in the management of patients with weight regain after bariatric surgery. Rev Col Bras Cir.

2013;40(3):191–5. https://doi.org/10.1590/s0100-69912013000300005.
130. Schwartz J, Chaudhry UI, Suzo A, Durkin N, Wehr AM, Foreman KS, et al. Pharmacotherapy in conjunction with a diet and exercise program for the treatment of weight recidivism or weight loss plateau post-bariatric surgery: a retrospective review. Obes Surg. 2016;26(2):452–8. https://doi.org/10.1007/s11695-015-1979-x.
131. Stanford FC, Alfaris N, Gomez G, Ricks ET, Shukla AP, Corey KE, et al. The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multicenter study. Surg Obes Relat Dis. 2017;13(3):491–500. https://doi.org/10.1016/j.soard.2016.10.018.
132. Nor Hanipah Z, Nasr EC, Bucak E, Schauer PR, Aminian A, Brethauer SA, et al. Efficacy of adjuvant weight loss medication after bariatric surgery. Surg Obes Relat Dis. 2018;14(1):93–8. https://doi.org/10.1016/j.soard.2017.10.002.
133. Srivastava G, Buffington C. A specialized medical management program to address post-operative weight regain in bariatric patients. Obes Surg. 2018;28(8):2241–6. https://doi.org/10.1007/s11695-018-3141-z.
134. Rye P, Modi R, Cawsey S, Sharma AM. Efficacy of high-dose liraglutide as an adjunct for weight loss in patients with prior bariatric surgery. Obes Surg. 2018;28(11):3553–8. https://doi.org/10.1007/s11695-018-3393-7.
135. Gazda CL, Clark JD, Lingvay I, Almandoz JP. Pharmacotherapies for post-bariatric weight regain: real-world comparative outcomes. Obesity (Silver Spring). 2021;29(5):829–36. https://doi.org/10.1002/oby.23146.
136. Rubio MA, Ramos-Leví AM. Initial experience with alternate-day liraglutide for weight regain following bariatric surgery. Obes Surg. 2021;31(9):4216–8. https://doi.org/10.1007/s11695-021-05535-2.